Peer-reviewed veterinary case report
Metabolic changes in hyperthyroid cats before and after iodine
By Bechtold, Molly A et al.·Published in PloS one·2024·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum metabolome analysis in hyperthyroid cats before and after radioactive iodine therapy.
- Species:
- cat
Plain-English summary
A 7-year-old cat with hyperthyroidism was treated with radioactive iodine therapy to help manage her condition. Before treatment, she showed distinct metabolic changes compared to healthy cats, with many metabolites being either increased or decreased. After the therapy, some of these metabolic changes persisted even though her thyroid levels returned to normal. This suggests that while the treatment was effective in managing her hyperthyroidism, it didn't completely resolve all metabolic issues. Further research is needed to understand the implications of these ongoing changes.
People also search for: cat hyperthyroidism treatment · radioactive iodine therapy for cats · cat metabolic changes after treatment
Abstract
Hyperthyroidism is the most common feline endocrinopathy. In hyperthyroid humans, untargeted metabolomic analysis identified persistent metabolic derangements despite achieving a euthyroid state. Therefore, we sought to define the metabolome of hyperthyroid cats and identify ongoing metabolic changes after treatment. We prospectively compared privately-owned hyperthyroid cats (n = 7) admitted for radioactive iodine (I-131) treatment and euthyroid privately-owned control (CON) cats (n = 12). Serum samples were collected before (T0), 1-month (T1), and three months after (T3) I-131 therapy for untargeted metabolomic analysis by MS/MS. Hyperthyroid cats (T0) had a distinct metabolic signature with 277 significantly different metabolites than controls (70 increased, 207 decreased). After treatment, 66 (T1 vs. CON) and 64 (T3 vs. CON) metabolite differences persisted. Clustering and data reduction analysis revealed separate clustering of hyperthyroid (T0) and CON cats with intermediate phenotypes after treatment (T1 & T3). Mevalonate/mevalonolactone and creatine phosphate were candidate biomarkers with excellent discrimination between hyperthyroid and healthy cats. We found several metabolic derangements (e.g., decreased carnitine and α-tocopherol) do not entirely resolve after achieving a euthyroid state after treating hyperthyroid cats with I-131. Further investigation is warranted to determine diagnostic and therapeutic implications for candidate biomarkers and persistent metabolic abnormalities.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38857299/